Immunic (IMUX) Income from Continuing Operations (2013 - 2026)

Immunic has disclosed Income from Continuing Operations across 14 years of filings, most recently posting 32475000.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 32475000.0, down 21.89% year-over-year; the trailing twelve-month figure through Mar 2026 was 108021000.0 (down 9.54% YoY), and the FY2025 annual result was 102188000.0, down 7.95% from the prior year.
• Income from Continuing Operations came in at 32475000.0 for Q1 2026 at Immunic, down from 23130000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 19886000.0 in Q3 2022 to a low of 56629000.0 in Q4 2022.
• The 5-year median for Income from Continuing Operations is 24053000.0 (2023), against an average of 26112941.18.
• Across the five-year window, Income from Continuing Operations sank 160.89% in 2022 and soared 59.67% in 2023, its largest moves.
• Immunic's Income from Continuing Operations stood at 56629000.0 in 2022, then jumped by 59.67% to 22840000.0 in 2023, then decreased by 10.34% to 25202000.0 in 2024, then increased by 8.22% to 23130000.0 in 2025, then slumped by 40.4% to 32475000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 32475000.0 (Q1 2026), 23130000.0 (Q4 2025), and 25574000.0 (Q3 2025), per Business Quant data.